EF5 PET of Tumor Hypoxia: A Predictive Imaging Biomarker of Response to Stereotactic Ablative Radiotherapy (SABR) for Early Lung Cancer

Abstract

Stereotactic ablative radiotherapy (SABR) has become a new standard of care for early stage lung cancer in patients who are not candidates for surgery because of excessive surgical risk, and will be an important treatment option for a growing segment of patients with lung cancer. This is particularly true as lung cancer screening efforts are expected to diagnose a greater proportion of lung cancers at earlier stages, yet the aging of the population will lead to a greater proportion of patients having comorbidities that increase surgical risk. Tumor hypoxia is a major known mechanism of radiation resistance and is especially expected to affect very short courses of radiation as in SABR. Imaging using a third-generation hypoxia PET agent, 18F-EF5,is a promising approach for noninvasive hypoxia measurement that needs to be validated in the clinical setting.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Nov 01, 2017
Accession Number
AD1047610

Entities

People

  • Billy Jr W. Loo

Organizations

  • Stanford University

Tags

DTIC Thesaurus Topics

  • Biological Markers
  • Biomedical Research
  • Cancer Screening
  • Demographic Cohorts
  • Department Of Defense
  • Intervention
  • Lung Cancer
  • Medical Personnel
  • Metastasis
  • Neoplasms
  • Radiation
  • Radiation Oncology
  • Radiation Resistance
  • Radiotherapy
  • Standards
  • Survival
  • Therapy

Fields of Study

  • Medicine
  • Physics

Readers

  • Oncology (Cancer Research).
  • Oncology and Biomarker-Based Cancer Detection.
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.